CoChat
Sign Up
Cited by 13Opioid Use Disorder TreatmentHealthcare Policy and ManagementPharmaceutical Economics and Policy

The DOI matches its Crossref record; 66 of the 75 references it cites were found in a registry or an index, and 9 are not checked yet.

Addiction, Thick Market Externalities, and the Persistence of the Opioid Epidemic

Open access
Cutler, David, Donahoe, J. Travis·2024·National Bureau of Economic Research
DOI 10.3386/w32055
Open this paper in CoChat — free account

Abstract

We also thank Beau Kilmer for helping us access time-series data on fentanyl prices.Cutler was involved in multi-district litigation regarding opioids as an expert witness to the plaintiff counties suing opioid manufacturers

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3386/w32055

Cites

66 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Thick market externalities theory posits that more users and suppliers lead to easier access to drugs, increased availability of drug-related information, and lower stigma associated with drug use, all of which attract even more participants to the illegal drug market.

    “as suggested by the thick market externalities theory.23 This theory posits that more users and suppliers lead to easier access to drugs, increased availability of drug-related information, and lower stigma associated with drug use, all of which attract even more participants to the illegal drug market.”

    From Safer Opioid Supply, Subsequent Drug Decriminalization, and Opioid Overdoses (2025) · cites this paper as [23]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Angrist, Joshua D., and Jörn-Steffen Pischke. 2009. Mostly Harmless Econometrics: An Empiricist's Companion. Princeton university press.
  2. Buchmueller, Thomas C., and Colleen Carey. 2018. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare." American Economic Journal: Economic Policy 10(1):77-112.
  3. Cawley, John, and Christopher J. Ruhm. 2011. "Chapter Three -The Economics of Risky Health Behaviors." Pp. 95-199 in Handbook of Health Economics. Vol. 2, Handbook of Health Economics, edited by M. V. Pauly, T. G. Mcguire, and P. P. Barros. Elsevier. Charles, Kerwin Kofi, Erik Hurst, and Mariel Schwartz. 2019. "The Transformation of Manufacturing and the Decline in US Employment." NBER Macroeconomics Annual 33(1):307-72.
  4. Compton, Wilson M., and Christopher M. Jones. 2019. "Epidemiology of the US Opioid Crisis: The Importance of the Vector." Annals of the New York Academy of Sciences 1451(1):130-43.
  5. Courtwright, David T. 2009. Dark Paradise. Harvard University Press.
  6. Currie, Janet, and Hannes Schwandt. 2021. "The Opioid Epidemic Was Not Caused by Economic Distress but by Factors That Could Be More Rapidly Addressed." The ANNALS of the American Academy of Political and Social Science 695(1):276-91.
  7. Drukker, David M., Hua Peng, Ingmar R. Prucha, and Rafal Raciborski. 2013. "Creating and Managing Spatial-Weighting Matrices with the Spmat Command." The Stata Journal 13(2):242-86.
  8. Fingerhut, Lois A., and Christine S. Cox. 1998. "Poisoning Mortality, 1985-1995." Public Health Reports 113(3):218.
  9. Hoyert, Donna L., Elizabeth Arias, Betty L. Smith, Sherry L. Murphy, and Kenneth D. Kochanek. 2001. "Deaths: Final Data for 1999 (National Vital Statistics Reports, Vol. 49, No. 8)." Hyattsville, MD: National Center for Health Statistics.
  10. Mars, Sarah G., Philippe Bourgois, George Karandinos, Fernando Montero, and Daniel Ciccarone. 2014. "'Every 'Never'I Ever Said Came True': Transitions from Opioid Pills to Heroin Injecting." International Journal of Drug Policy 25(2):257-66.
  11. Mars, Sarah, Jeff Ondocsin, Nicole Holm, and Daniel Ciccarone. 2024. "The Influence of Transformations in Supply on Methamphetamine Initiation among People Injecting Opioids in the United States." Harm Reduction Journal 21(1):1-13.
  12. Miller, Jacob N. 2020. "The War on Drugs 2.0: Darknet Fentanyl's Rise and the Effects of Regulatory and Law Enforcement Action." Contemporary Economic Policy 38(2):246-57.
  13. Ondocsin, Jeff, Nicole Holm, Sarah G. Mars, and Daniel Ciccarone. 2023. "The Motives and Methods of Methamphetamine and 'Heroin'Co-Use in West Virginia." Harm Reduction Journal 20(1):88.
  14. Pierce, Justin R., and Peter K. Schott. 2020. "Trade Liberalization and Mortality: Evidence from US Counties." American Economic Review: Insights 2(1):47-64.
  15. Zhu, Wenjia, Michael E. Chernew, Tisamarie B. Sherry, and Nicole Maestas. 2019. "Initial Opioid Prescriptions among US Commercially Insured Patients, 2012-2017." New England Journal of Medicine 380(11):1043-52.
  16. Zoorob, Michael. 2019. "Fentanyl Shock: The Changing Geography of Overdose in the United States." International Journal of Drug Policy 70:40-46.

Cited by

Sorted by citations

Related

Metadata

Authors
Cutler, D., & Donahoe, J. T.
Affiliations
National Bureau of Economic Research (US)
ORCID
Venue
National Bureau of Economic Research
Publisher
National Bureau of Economic Research
Published
2024-01
DOI
10.3386/w32055
OpenAlex
W4391116686
Cited by
13
References
73
Citations by year
2026: 1 · 2025: 4 · 2024: 6
Type
report
Language
en
Open access
Locations
National Bureau of Economic Research (publishedVersion)
Funders
  • National Institutes of Health (R36HS029104)
  • Agency for Healthcare Research and Quality (T32HS000055, T32MH019733)
  • National Institute on Aging (T32AG000186, P01AG005842)
  • National Institute of Mental Health (T32HS000055, T32MH019733)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
opioid epidemic, addiction, pharmaceutical litigation, multidistrict litigation, expert testimony, pharmaceutical industry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review